65,437 trials
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) — -0.025; 0.062; 0.099 L — p=<0.0001
HIV-1 and Hepatitis C Co-Infection
Primary: The Proportion of All Subjects With HCV Viral Load < 60 IU/mL at Week 24 of Step 2. — 0.158 proportion of participants — p=0.29
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1) — 0.034; 0.072 L
Arm Lymphedema · Truncal Lymphedema · Breast Cancer
Primary: Arm Volume at End of Study — 2376.52; 2539.93 ml
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorders
Primary: Change in Waist Circumference — 106.09; 108.37 cm
Atopic Dermatitis
Primary: Changes in SCORAD Index — -3.0; -5.7 units on a scale
Pain · Cancer
Primary: The Incidence of Adverse Events as a Measure of Subject Safety — 37; 4 participants
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) Determined by an Independent Review Facility — 18.5; 12.4 Months — p=<0.0001
Schizophrenia · Insulin Resistance
Primary: Change in Total Cholesterol — -15.3; 5.6 mg/dL — p=0.125
Stroke
Primary: 10-meter Walking Test (10mWT) — 0.20; 0.18; 0.19; 0.20 meters per second (m/s)
Bladder, Neurogenic
Primary: Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day. — 35.3; 45.7…
Primary Renal Transplant
Primary: Number of Participants With Biopsy Proven Rejection — 2; 7 participants
Adrenal Cortex Neoplasms
Primary: Percentage of Participants With a Partial or Complete Response — 4; 6 Percentage of participants
Cardiovascular Diseases · Depression · Heart Diseases
Primary: Beck Depression Inventory-II — 16.1; 14.8 units on a scale
Arthritis, Rheumatoid · Spondylitis, Ankylosing · Arthritis, Psoriatic
Primary: Number of Participants Experiencing at Least One Adverse Event — 609 Participants